BNB Plus Corp. Announces Historic Shipment of LineaDNA™
1. Record Achievement Highlights Operational Excellence
BNB Plus Corp. (Nasdaq: BNBX), formerly known as Applied DNA Sciences, Inc., has made headlines today with the announcement of its largest single shipment of LineaDNA™ in the company’s history, valued at over $390,000 USD. This significant milestone not only showcases the company’s manufacturing capabilities but also underscores its commitment to advancing the biopharmaceutical and diagnostics sectors.
2. Details of the Shipment
The shipment, weighing approximately 5 grams, was produced by BNB Plus’s subsidiary, LineaRx, Inc., as part of a previously disclosed supply agreement for the bulk manufacture of LineaDNA. This DNA is utilized as a functional component in cancer diagnostic tests, which are increasingly vital in the fight against cancer.
Clay Shorrock, President and CEO of BNBX, expressed confidence in the company’s operations, stating, “We believe this record LineaDNA shipment reflects the operational excellence and disciplined execution that define the Company.” He emphasized the organization’s resilience in fulfilling this record order, even while taking steps to right-size operations in response to prevailing market conditions.
3. Future Expectations
The company anticipates further multi-gram deliveries under the Supply Agreement in the first half of 2026, which bodes well for its growth trajectory. Such deliveries are crucial not only for meeting the increasing demand in the diagnostics industry but also for solidifying BNB Plus's position as a leader in nucleic acid production.
4. Understanding the LineaDNA™ Platform
The LineaDNA platform is a proprietary, cell-free DNA production system that leverages BNB Plus’s extensive expertise in large-scale polymerase chain reaction (PCR) technology. Unlike traditional plasmid-based DNA production methods, LineaDNA produces high-fidelity DNA that is free of adventitious sequences and is rapidly scalable. This innovative platform can generate DNA ranging from 100 base pairs to 20 kilobases in quantities from milligrams to grams, adhering to rigorous quality standards such as Research Use Only (RUO), Good Laboratory Practice (GLP), and Good Manufacturing Practice (GMP).
5. BNB Plus Corp.: A New Era
As BNB Plus continues to evolve, it aims to unlock streamlined access to the Binance ecosystem, providing innovative yield strategies and long BNB exposure. The company’s strategy combines sophisticated decentralized finance (DeFi) yield generation with Binance-native opportunities, thereby granting investors access to high-performance digital assets that were previously out of reach.
The transformation from Applied DNA Sciences to BNB Plus signifies a broader strategic shift towards harnessing blockchain technology and digital assets, positioning the company at the forefront of this rapidly evolving market.
6. Conclusion
BNB Plus Corp.'s announcement of its largest shipment of LineaDNA marks a significant achievement in its operational journey. The company’s innovative approach to DNA production, coupled with its strategic focus on digital assets and decentralized finance, sets the stage for continued growth and expansion in the biopharmaceutical and diagnostics markets. As it moves forward, investors and stakeholders alike will be keenly watching how BNB Plus capitalizes on its recent successes and navigates the evolving landscape of digital finance.
